NEW YORK, NY / ACCESSWIRE / March 10, 2016 / SeeThruEquity, a leading independent equity research and corporate access firm focused on smallcap and microcap public companies, today announced it has issued an update note on Amarantus BioScience Holdings, Inc. AMBS.
The report is available here: AMBS March 2016 Update Note. SeeThruEquity is an approved equity research contributor on Thomson First Call, Capital IQ, FactSet, and Zack's. The report will be available on these platforms. The firm also contributes its estimates to Thomson Estimates, the leading estimates platform on Wall Street.
Highlights from the note are as follows:
Avant Diagnostics and Amarantus Diagnostics to combine operations with Theranostics Health
Amarantus Diagnostics, a wholly-owned subsidiary of Amarantus BioScience Holdings, and Avant Diagnostics announced they have jointly entered into a Letter of Intent for Avant to acquire assets and certain liabilities of Theranostics Health Incorporated. The combination will add key CLIA laboratory and intellectual property capabilities to the impending merger between Amarantus Diagnostics and Avant Diagnostics. According to the LOI, upon closing Avant will issue to Theranostics 25 million shares and Amarantus has provided a $400,000 convertible note. The transaction is expected to close in the first half of 2016.
Theranostics works with 7 of the 10 largest pharmaceutical companies (based on revenue) and generates over $1.5mn in services revenue. Theranostics business is centered on providing pharmaceutical and biotechnical companies access to its technology for qualitatively measuring the activation status of key proteins and signal transduction pathways that are dysregulated in multiple disease processes via its Reverse-phase Protein Array (RPPA) platform.
The combined company will have a robust pipeline of oncology and neurology diagnostics, with 3 proprietary diagnostic tests for ovarian cancer, multiple sclerosis, and Alzheimer's disease. In 2016, CLIA-enabling validation studies are expected to be initiated for OvaDx, MSPrecise and LymPro Test, with product launch in 2017. The scientific focus is on becoming a recognized leader in the field of cell cycle biology research, driven largely by Theralink for oncology and LymPro Test for Alzheimer's.
Orphan drug designation for eltoprazine
The Company announced on February 10, 2016, that it has received orphan drug designation from the US FDA for eltoprazine in the treatment of Parkinson's disease levodopa-induced dyskinesia (PD-LID).
Rare pediatric disease designation request
AMBS recently announced that it has requested Rare Pediatric Disease Designation (RPDD) from the US Food and Drug Administration (FDA) for treating retinitis pigmentosa (RP) with MANF.
European patents for Amarantus' Engineered Skin Substitute
The Cutanogen Corporation, a wholly owned subsidiary of AMBS, has announced on February 3, 2016, that it has received 2 Intent to Grant a Patent notices from the European Patent Officer for Engineered Skin Substitute (ESS). The notices cover the parent patent application entitled "A method of producing a cultured skin device" and an associated divisional patent filing. The Company expects both patents to be issued later in 2016 and to add key elements to their barrier-to-entry strategy for this technology.
Issuance of Chinese patent
On January 29, 2016, the Company disclosed the issuance of a Chinese patent named "Neurodegenerative Disorders" that it is for the use of MANF for the treatment of Parkinson's disease and other neurodegenerative conditions. The patent also covers MANF protein therapy, gene therapy and cell therapy applications into 2029.
New investments
The Company recently announced the closing of a $3mn investment, and a $1mn investment from an investor introduced by International Infusion, LLC.
Please review important disclosures at www.seethruequity.com.
About Amarantus BioScience Holdings, Inc.
Amarantus BioScience Holdings (AMBS) is a biotechnology company developing treatments and diagnostics for diseases in the areas of neurology and orphan diseases. AMBS' Therapeutics division has development rights to eltoprazine, a small molecule currently in a Phase 2b clinical program for Parkinson's disease levodopa-induced dyskinesia and with the potential to expand into adult ADHD and Alzheimer's aggression. The Company has an exclusive worldwide license to intellectual property rights associated to Engineered Skin Substitute (ESS), an orphan drug designated autologous full thickness skin replacement product in development for the treatment of severe burns currently preparing to enter Phase 2 clinical studies. AMBS owns the intellectual property rights to a therapeutic protein known as mesencephalic-astrocyte-derived neurotrophic factor (MANF) and is developing MANF as a treatment for orphan ophthalmic disorders, initially in retinitis pigmentosa (RP). AMBS also owns the discovery of neurotrophic factors (PhenoGuard(TM)) that led to MANF's discovery.
AMBS' Diagnostics division owns the rights to MSPrecise(R), a proprietary next-generation DNA sequencing (NGS) assay for the identification of patients with relapsing-remitting multiple sclerosis (RRMS) at first clinical presentation, has an exclusive worldwide license to the Lymphocyte Proliferation test (LymPro Test(R)) for Alzheimer's disease, which was developed by Prof. Thomas Arendt, Ph.D., from the University of Leipzig, and owns intellectual property for the diagnosis of Parkinson's disease (NuroPro).
For further information please visit www.Amarantus.com, or connect with the Company on Facebook, LinkedIn, Twitter and Google+.
About SeeThruEquity
SeeThruEquity is an equity research and corporate access firm focused on companies with less than $1 billion in market capitalization. The research is not paid for and is unbiased. The company does not conduct any investment banking or commission based business. SeeThruEquity is approved to contribute its research to Thomson One Analytics (First Call), Capital IQ, FactSet, Zacks, and distribute its research to its database of opt-in investors. The company also contributes its estimates to Thomson Estimates, the leading estimates platform on Wall Street.
For more information visit www.seethruequity.com.
Contact:
Ajay Tandon
SeeThruEquity
info@seethruequity.com
SOURCE: SeeThruEquity
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
